Company intelligence / Profile preview

SPARTA Biodiscovery

London, England, United Kingdomspartabiodiscovery.com ↗

Ownership: Private
Development stage: Commercial

Overview

SPARTA Biodiscovery commercializes the SPARTA® platform—a benchtop instrument and analytical service that enables automated single-particle chemical characterization of nanoformulations. This technology supports R&D and quality control in next-generation nanomedicine development by providing detailed data on nanoparticle composition, drug loading, heterogeneity, and stability. It is designed to accelerate the development of advanced therapeutics such as cancer treatments, gene therapies, and vaccines.

Modalities: NanoparticleSmall moleculesmRNA-based drugsGene therapiesViral vectorsExosomes
Industry: Drug Discovery Services

Partnerships

Sartorius (investor/partner)Waters Corporation (collaboration on integrated analytical solutions)

Beyond the preview

Go deeper on SPARTA Biodiscovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARTA Biodiscovery.

Explore the full profile